New therapies are reshaping care for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis, yet compensated cirrhosis remains a frontier with no approved pharmacologic option. Fibroblast growth factor 21 (FGF21) analogues are a closely watched investigational class targeting both metabolic …
What if the neuropathy in front of you isn’t what it seems? Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune-mediated peripheral neuropathy, yet it remains widely underrecognized. Because its symptoms mimic other neuropathies, CIDP is too often misdiagnosed …
Major depressive disorder (MDD) is often recurrent, and achieving remission does not eliminate the risk of future episodes. Each recurrent episode can deepen the neurobiological, psychiatric, medical, economic, and quality-of-life burden while increasing the risk of future episodes. Yet, relapse …
Generalized myasthenia gravis (gMG) is a chronic autoimmune neuromuscular disease that can profoundly disrupt strength and independence through unpredictable, fluctuating muscle weakness. Recent advances have transformed the treatment landscape, with targeted therapies such as neonatal Fc receptor (FcRn) inhibitors and …
The obesity pipeline is moving faster than the evidence can be absorbed. A new class of amylin-based agents — investigational therapies now advancing through phase 2 and phase 3 trials with several studied both on their own and in combination …
Obesity looks like one diagnosis but behaves like many. Two patients with the same body mass index (BMI) can respond very differently to the same medication, and as the treatment armamentarium expands, from today’s incretins to the amylin-based and combination …
Anti-vascular endothelial growth factor (anti-VEGF) therapy transformed the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), but it has not solved either disease. Roughly 40% to 60% of patients with DME and 40% to 50% with …
Anti-vascular endothelial growth factor (anti-VEGF) therapy transformed the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD), but it has not solved either disease. Roughly 40% to 60% of patients with DME and 40% to 50% with …
The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has historically been anchored by surgery, radiation therapy, and chemoradiation. Care for this complex disease requires navigating diverse tumor biology, multiple sites of origin, and significant …